CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Rhea-AI Summary
CVRx (NASDAQ: CVRX) announced that its management team will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami on Wednesday, June 10, 2026, at 8:00 a.m. ET.
A live webcast and limited-time archived replay will be available at ir.cvrx.com.
Positive
- None.
Negative
- None.
News Market Reaction – CVRX
In the May 28 session, CVRX declined 2.60%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 20 | Investor conference | Neutral | +0.2% | Announcement of presentation at William Blair growth stock conference. |
| May 14 | Coverage expansion | Positive | +10.0% | Humana Medicare Advantage coverage policy for Barostim therapy. |
| May 11 | Quarterly earnings | Positive | -23.8% | Q1 2026 results with 20% revenue growth and updated guidance. |
| May 4 | Clinical trial start | Positive | -3.8% | First patient enrollment in large BENEFIT-HF heart failure trial. |
| Apr 27 | Earnings date notice | Neutral | -2.2% | Scheduled date and call details for Q1 2026 results. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows strong positive reactions to reimbursement wins but selloffs or softness around earnings and major clinical updates, indicating occasional divergence between seemingly positive fundamentals and short-term price moves.
Over the past month, CVRx issued several key updates. A Humana Medicare Advantage coverage policy for Barostim on May 14 drove a +9.96% move, contrasting with a -23.84% reaction to Q1 2026 earnings on May 11 despite revenue growth. The BENEFIT-HF first enrollment news on May 4 led to a -3.78% move. Conference announcements on April 27 and May 20 had modest impacts, framing today’s Goldman Sachs conference appearance as part of an ongoing investor outreach cadence.
Key Terms
neuromodulation medical
cardiovascular diseases medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MINNEAPOLIS, May 27, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that the management team will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami on Wednesday, June 10, 2026. The Company's presentation will begin at 8:00 a.m. (ET).
A live webcast of the event can be found at ir.cvrx.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time.
About CVRx, Inc.
CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure.
Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
Investor Contact:
Mark Klausner or Mike Vallie
ICR Healthcare
443-213-0501
ir@cvrx.com
Media Contact:
Emily Meyers
CVRx, Inc.
763-416-2853
emeyers@cvrx.com
